Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 8 | 2023 | 138 | 2.310 |
Why?
|
| NADPH Oxidases | 7 | 2020 | 109 | 2.300 |
Why?
|
| Tissue Engineering | 7 | 2009 | 152 | 1.300 |
Why?
|
| Myofibroblasts | 4 | 2020 | 62 | 1.070 |
Why?
|
| Aging | 5 | 2021 | 1236 | 1.060 |
Why?
|
| Biomedical Technology | 1 | 2024 | 38 | 0.800 |
Why?
|
| Pulmonary Medicine | 1 | 2024 | 33 | 0.790 |
Why?
|
| Oxidative Stress | 6 | 2020 | 793 | 0.720 |
Why?
|
| Indoles | 2 | 2024 | 200 | 0.690 |
Why?
|
| Cellular Senescence | 3 | 2020 | 217 | 0.680 |
Why?
|
| Cell Differentiation | 5 | 2020 | 1910 | 0.640 |
Why?
|
| Bioartificial Organs | 3 | 2008 | 10 | 0.550 |
Why?
|
| Lung Diseases | 3 | 2017 | 397 | 0.540 |
Why?
|
| MyoD Protein | 2 | 2020 | 22 | 0.500 |
Why?
|
| Acute Lung Injury | 2 | 2017 | 68 | 0.490 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2015 | 137 | 0.490 |
Why?
|
| Ubiquitination | 1 | 2017 | 174 | 0.470 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2008 | 171 | 0.450 |
Why?
|
| Pulmonary Fibrosis | 2 | 2013 | 113 | 0.430 |
Why?
|
| Myocardium | 3 | 2008 | 858 | 0.420 |
Why?
|
| Heart | 2 | 2009 | 659 | 0.410 |
Why?
|
| Perfusion | 3 | 2009 | 209 | 0.380 |
Why?
|
| Lung Injury | 2 | 2014 | 123 | 0.360 |
Why?
|
| Oxidation-Reduction | 3 | 2020 | 434 | 0.360 |
Why?
|
| Biomedical Research | 2 | 2008 | 556 | 0.360 |
Why?
|
| Creativity | 2 | 2008 | 12 | 0.340 |
Why?
|
| Regeneration | 2 | 2011 | 227 | 0.340 |
Why?
|
| Reactive Oxygen Species | 5 | 2020 | 526 | 0.340 |
Why?
|
| Fibroblasts | 6 | 2022 | 852 | 0.330 |
Why?
|
| Lung | 4 | 2023 | 1533 | 0.310 |
Why?
|
| NADPH Oxidase 4 | 3 | 2017 | 13 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 7 | 2024 | 4693 | 0.290 |
Why?
|
| Leadership | 2 | 2008 | 246 | 0.290 |
Why?
|
| Fibrin | 3 | 2022 | 64 | 0.290 |
Why?
|
| Environment Design | 1 | 2008 | 16 | 0.280 |
Why?
|
| Cells, Cultured | 9 | 2024 | 2887 | 0.280 |
Why?
|
| Organizational Policy | 1 | 2008 | 50 | 0.280 |
Why?
|
| Policy Making | 1 | 2008 | 60 | 0.280 |
Why?
|
| Organizational Objectives | 1 | 2008 | 35 | 0.270 |
Why?
|
| Fibrosis | 4 | 2022 | 419 | 0.270 |
Why?
|
| Animals | 19 | 2024 | 33698 | 0.270 |
Why?
|
| Apoptosis | 6 | 2020 | 1830 | 0.270 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 85 | 0.260 |
Why?
|
| Diffusion of Innovation | 1 | 2008 | 83 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 383 | 0.250 |
Why?
|
| Epithelial Cells | 4 | 2020 | 907 | 0.250 |
Why?
|
| Myocardial Contraction | 4 | 2009 | 242 | 0.250 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2008 | 224 | 0.250 |
Why?
|
| Zebrafish | 1 | 2008 | 414 | 0.240 |
Why?
|
| Humans | 27 | 2024 | 130154 | 0.220 |
Why?
|
| Aorta | 1 | 2008 | 522 | 0.220 |
Why?
|
| Transforming Growth Factor beta1 | 4 | 2022 | 142 | 0.210 |
Why?
|
| Fecal Incontinence | 1 | 2005 | 71 | 0.210 |
Why?
|
| Anal Canal | 1 | 2005 | 87 | 0.210 |
Why?
|
| Endothelial Cells | 3 | 2024 | 520 | 0.210 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2024 | 65 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 479 | 0.170 |
Why?
|
| Fibrinolysis | 1 | 2021 | 44 | 0.170 |
Why?
|
| Cicatrix | 1 | 2022 | 124 | 0.160 |
Why?
|
| Hydrogen Peroxide | 2 | 2013 | 116 | 0.160 |
Why?
|
| Mucin 5AC | 1 | 2020 | 23 | 0.160 |
Why?
|
| Mucin-1 | 1 | 2020 | 32 | 0.160 |
Why?
|
| Rats | 5 | 2024 | 3378 | 0.160 |
Why?
|
| Goblet Cells | 1 | 2020 | 105 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 378 | 0.140 |
Why?
|
| Myocytes, Cardiac | 3 | 2008 | 671 | 0.140 |
Why?
|
| Group Processes | 2 | 2008 | 48 | 0.140 |
Why?
|
| Cell Line | 2 | 2020 | 2554 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2020 | 824 | 0.130 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2017 | 25 | 0.130 |
Why?
|
| Bioprosthesis | 2 | 2008 | 110 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2017 | 64 | 0.130 |
Why?
|
| Cooperative Behavior | 2 | 2008 | 222 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 614 | 0.120 |
Why?
|
| Ubiquitin | 1 | 2017 | 129 | 0.120 |
Why?
|
| Reperfusion | 1 | 2016 | 26 | 0.120 |
Why?
|
| Mice, Knockout | 1 | 2024 | 3814 | 0.120 |
Why?
|
| Motivation | 2 | 2008 | 328 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 237 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 277 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 304 | 0.110 |
Why?
|
| Smoking | 1 | 2020 | 927 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 360 | 0.110 |
Why?
|
| Smad3 Protein | 2 | 2017 | 53 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 450 | 0.100 |
Why?
|
| Lower Extremity | 1 | 2016 | 184 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2017 | 4656 | 0.100 |
Why?
|
| Models, Biological | 2 | 2017 | 1376 | 0.100 |
Why?
|
| Ischemia | 1 | 2016 | 362 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2024 | 2463 | 0.090 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2013 | 75 | 0.090 |
Why?
|
| Rats, Inbred F344 | 2 | 2009 | 99 | 0.090 |
Why?
|
| Aged | 2 | 2020 | 20833 | 0.090 |
Why?
|
| Antioxidants | 1 | 2014 | 334 | 0.090 |
Why?
|
| Sepsis | 1 | 2016 | 496 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2012 | 422 | 0.080 |
Why?
|
| Bioreactors | 2 | 2008 | 43 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 747 | 0.080 |
Why?
|
| Phenotype | 3 | 2017 | 4464 | 0.080 |
Why?
|
| Equipment Design | 2 | 2008 | 510 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2024 | 1110 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 559 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2008 | 273 | 0.070 |
Why?
|
| Histones | 1 | 2013 | 541 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2009 | 212 | 0.070 |
Why?
|
| Sympathomimetics | 1 | 2008 | 10 | 0.070 |
Why?
|
| Facility Design and Construction | 1 | 2008 | 6 | 0.070 |
Why?
|
| Isoproterenol | 1 | 2008 | 85 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 965 | 0.070 |
Why?
|
| Staff Development | 1 | 2008 | 50 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2008 | 14 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2008 | 234 | 0.070 |
Why?
|
| Gels | 1 | 2008 | 59 | 0.070 |
Why?
|
| Infusion Pumps | 1 | 2008 | 31 | 0.070 |
Why?
|
| United States | 1 | 2024 | 11885 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 169 | 0.070 |
Why?
|
| Heart Valves | 1 | 2008 | 52 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2008 | 92 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 1546 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 761 | 0.070 |
Why?
|
| Heart, Artificial | 1 | 2008 | 46 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 662 | 0.060 |
Why?
|
| Extracellular Matrix | 2 | 2022 | 232 | 0.060 |
Why?
|
| Regenerative Medicine | 1 | 2007 | 37 | 0.060 |
Why?
|
| Pluripotent Stem Cells | 1 | 2007 | 77 | 0.060 |
Why?
|
| Cell Survival | 1 | 2008 | 832 | 0.060 |
Why?
|
| Muscle Relaxation | 1 | 2005 | 11 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2008 | 401 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2020 | 1571 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2005 | 69 | 0.050 |
Why?
|
| Mice | 4 | 2024 | 18172 | 0.050 |
Why?
|
| RNA | 1 | 2008 | 511 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2005 | 140 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 2323 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2009 | 2553 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2005 | 145 | 0.050 |
Why?
|
| Rabbits | 1 | 2005 | 573 | 0.050 |
Why?
|
| Vascular Remodeling | 1 | 2024 | 46 | 0.050 |
Why?
|
| Oximes | 1 | 2024 | 56 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 197 | 0.050 |
Why?
|
| Kinetics | 1 | 2005 | 1085 | 0.050 |
Why?
|
| Trematoda | 1 | 2002 | 1 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1070 | 0.050 |
Why?
|
| Ranidae | 1 | 2002 | 6 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 165 | 0.050 |
Why?
|
| Colon | 1 | 2005 | 363 | 0.050 |
Why?
|
| Female | 3 | 2020 | 70285 | 0.040 |
Why?
|
| Limb Deformities, Congenital | 1 | 2002 | 115 | 0.040 |
Why?
|
| Collagen | 1 | 2022 | 274 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 437 | 0.040 |
Why?
|
| Middle Aged | 2 | 2020 | 28331 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2020 | 118 | 0.040 |
Why?
|
| Epithelium | 1 | 2020 | 336 | 0.040 |
Why?
|
| Metaplasia | 1 | 2020 | 215 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2024 | 455 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 1159 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2020 | 285 | 0.040 |
Why?
|
| Male | 3 | 2024 | 64397 | 0.030 |
Why?
|
| Wound Healing | 1 | 2021 | 486 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2193 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2017 | 112 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 104 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 576 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2016 | 134 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 409 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 2094 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 4646 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2013 | 4 | 0.020 |
Why?
|
| Actin Cytoskeleton | 1 | 2013 | 49 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2013 | 64 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2013 | 113 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2013 | 47 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 3714 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 72 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2013 | 149 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1392 | 0.020 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 1992 | 113 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1481 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 647 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 237 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1992 | 345 | 0.020 |
Why?
|
| Oxygen | 1 | 2014 | 549 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1992 | 313 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2013 | 695 | 0.020 |
Why?
|
| Respiratory System | 1 | 2009 | 95 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1104 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 108 | 0.020 |
Why?
|
| Flow Injection Analysis | 1 | 2008 | 3 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2008 | 37 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2008 | 79 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 6178 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 196 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 12843 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 3360 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4848 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1933 | 0.010 |
Why?
|
| Trematode Infections | 1 | 2002 | 1 | 0.010 |
Why?
|
| Ecology | 1 | 2002 | 12 | 0.010 |
Why?
|
| Host-Parasite Interactions | 1 | 2002 | 71 | 0.010 |
Why?
|
| Larva | 1 | 2002 | 240 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2002 | 191 | 0.010 |
Why?
|
| Environmental Pollutants | 1 | 2002 | 78 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2002 | 220 | 0.010 |
Why?
|
| Hypertension | 1 | 2009 | 1349 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 10953 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1992 | 65 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1992 | 306 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 806 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1992 | 1013 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 1454 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1992 | 688 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1992 | 2390 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 3463 | 0.000 |
Why?
|
| Adult | 1 | 1992 | 31042 | 0.000 |
Why?
|